KONOWIECKI JOSEPH S sold $575K of ALHC

KONOWIECKI JOSEPH S (EVP, Corporate Affairs) sold 25,000 shares of Alignment Healthcare, Inc. (ALHC) at $23.00 ($0.58M total) on 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KONOWIECKI JOSEPH S
Published Jun 26, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Neutral
medium confidence
Mentioned
$ALHC
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling volume and price, but it does not introduce new guidance, earnings, or regulatory developments.

02

Market read

A routine 10b5-1 open-market sale may slightly pressure sentiment, but it is unlikely to drive a fundamental repricing by itself.

03

What to watch

Traders may over-weight insider sales; the filing lacks any accompanying narrative about performance, outlook, or risk changes.

Relevance 4/10Novelty 3/10Timing: filed 2026-06-26, after-hours/close window

Background

This is an SEC Form 4 insider transaction for Alignment Healthcare, Inc. (ALHC) by Joseph S. Konowiecki, EVP Corporate Affairs.

Company-level read

Ticker impact

$ALHCNeutralMedium confidence
Context

Alignment Healthcare disclosed an EVP corporate affairs open-market sale of 25,000 shares at $23 on 2026-06-26 under a 10b5-1 plan.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling accelerates or is paired with other disclosures.

Evidence & confidence

Form 4 shows a pre-arranged 10b5-1 sale and provides no new company fundamentals, guidance, or regulatory/contract event.

Market effects

No clear sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • Alignment Healthcare, Inc.

    Subject of the Form 4 insider sale disclosure.

  • KONOWIECKI JOSEPH S

    EVP, Corporate Affairs who sold 25,000 shares at $23.00 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMedAI 8/10

Alignment Healthcare (ALHC) Q3 2026 Earnings Call Transcript

Alignment Healthcare (ALHC) reported Q3 2026 earnings, with revenue of $1.4B (up 37% YoY) and adjusted gross profit of $142M. The company lowered annual guidance due to higher costs, targeting adjusted gross profit of at least $575M and adjusted EBITDA of $100M. Membership grew 31% YoY to 301,200. ALHC is addressing cost pressures and investing in clinical programs for 2027 growth.

$ALHCMedAI 8/10

What Alignment Healthcare (ALHC) Said on Its Q3 Earnings Call

Alignment Healthcare (ALHC) reduced its 2026 outlook, expecting at least $5.25B revenue, $575M adjusted gross profit, and $100M adjusted EBITDA. Q4 forecasts include 305K membership, $1.32B revenue, and $104M gross profit. Management targets 20% top-line growth in 2027, with plans to enter new markets and improve care model scalability. Stars ratings and provider alignment remain focus areas.